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Introduction
Parkinson disease (PD) is a common neurodegenerative
disease affecting about 1% of adults aged over 60 years1.
Although PD is primarily a movement disorder, depres-
sion in PD (dPD) is one of the most common psychiatric
symptoms that complicate the course of the illness.
Estimates of the prevalence of depression in patients
with PD vary widely from 2.7% to more than 90% because
of inconsistent sampling methods and case diagnoses2.
Considering the studies as a whole, the prevalence of
dPD is probably from 20% to 45%, with the lower fig-
ures relating to community-based studies3. Patients with
dPD have more severe neurologic symptoms than those
with PD and no depression, indicating an advanced
and widespread neurodegenerative process4.
Depression appears to be one of the most important
factors impairing the quality of life in patients with
PD; therefore, evaluating depression in these patients
is important5. Despite the frequency of dPD, there are
no uniformly accepted standards for treatment. Most
patients go untreated, and half of antidepressant users
remain depressed, suggesting that even when delivered,
treatment is often inadequate or ineffective6. There are
three main questions concerning the prescribing of an
antidepressant. The first is whether an antidepressant
can increase or induce parkinsonian symptoms. The sec-
ond is whether prescribing an antidepressant is safe in
a patient with PD. The third is how to choose an appro-
priate antidepressant for a PD patient with depression
and other medical comorbidities.
Screening and Diagnosis of dPD
The gold standard for establishing the diagnosis of de-
pression remains a structured interview using The Diag-
nostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV). DSM-IV diagnostic criteria for major
depression includes the persistent presence of five of the
following nine symptoms: depressed mood, diminished
interest in activities, significant weight gain or loss, in-
somnia or hypersomnia, psychomotor agitation or retar-
dation, fatigue or loss of energy, feelings of worthlessness
or inappropriate guilt, diminished ability to think or
concentrate, and recurrent thoughts of death7. It techni-
cally excludes a diagnosis of major depression in PD,
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because the depression is “associated with a medical
condition.” Nonetheless, the remaining DSM-IV criteria
can be used to evaluate and classify the depression8.
In general, lower prevalences are reported with study
designs using DSM-IV criteria.
The majority of patients with PD have non-major
depressive syndromes that include minor depression,
dysthymia, and subsyndromal depression9. These should
be taken seriously, because they are of clinical relevance
and are usually responsive to treatment. On the other
hand, many symptoms of depression (e.g., psychomo-
tor slowing, depressed mood, difficulty concentrating,
body weight loss, fatigue, or sleep disturbance) may also
be seen in PD without depression, which may cause
overdiagnosis in this group10. The National Institute of
Health-sponsored workshop recommended changes
to DSM-IV diagnostic criteria for use in dPD11. This report,
published in 2005, suggested the following: (1) use an
inclusive approach to symptom assessment (count a
symptom present regardless of whether it is believed
to be related to the underlying PD or depression); (2)
omit decreased interest as a core affective symptom
when diagnosing minor or subsyndromal depression;
(3) carry out assessments in the “on” state for patients
with motor fluctuations; and (4) use informants when
evaluating cognitively impaired patients.
One helpful tool to assess dPD is to use the time
patients spend in the waiting area to fill out one of the
many depression rating scales. Rating scales such as
the Beck Depression Inventory (BDI), the Montgomery-
Asberg Depression Rating Scale (MADRS), the Hamilton
Depression Rating Scale (HDRS), the Zung Self-rating
Depression Scale (SDS), the Unified Parkinson’s Disease
Rating Scale Part I, the Cornell Scale for the Assessment
of Depression in Dementia, the Center for Epidemiologic
Studies Depression Scale, the Hospital Anxiety and De-
pression Scale (HADS) and the Geriatric Depression
Scale (GDS) have been used to assess dPD12. These can
be easily scored by the physician or nurse and can be
used not only in the assessment of depression but also
to follow patients during treatment. For screening pur-
poses, the HDRS, BDI, HADS, MADRS, and GDS are valid
in dPD13. For measurement of severity of depressive
symptoms, the HDRS, MADRS, BDI and SDS are recom-
mended. It should also be noted that depression scales
should be interpreted with caution in the face of cogni-
tive impairment, as their validity is questionable under
these circumstances14. In addition, cut-off scores adjusted
for somatic and cognitive comorbidities are required.
The diagnosis of dPD should not be solely made on
the basis of a score on a rating scale.
Etiology of dPD
There is no consensus as to whether the etiology of
dPD is organic or reactive, or both15. Evidence against
the reactive hypothesis is the relative absence of guilt,
shame or sorrow that is associated with dPD and the
fact that depression can precede the diagnosis of
PD16,17. There is a greater degeneration of dopaminer-
gic neurons in the ventral mesencephalon in PD patients
who are depressed than in those who are not18. Although
levodopa is helpful in treating depression in a minor-
ity of PD patients, most do not exhibit a brisk response
to this therapy alone. Depression is also linked to a de-
crease in the activity of norepinephrine and serotonin.
Serotoninergic projections from the brainstem raphe
nuclei undergo degeneration in PD, which may be a key
abnormality in the etiology of dPD19. Structural brain-
stem midline alterations have also been detected in
both magnetic resonance images and transcranial sono-
grams in patients with primary depression and in those
with dPD, supporting a role of the median raphe nuclei 
in mood disorders20. Positron emission studies show
hypometabolism in the caudate and orbital-inferior
frontal lobe, reduced cortical 5-HT1A receptor binding
and a reduction in dopaminergic and noradrenergic
binding in the limbic system in dPD patients compared
with nondepressed PD patients21. Noradrenergic dys-
function may also be relevant to dPD given the known
pathologic involvement of the locus ceruleus22. The
locus ceruleus is the principal norepinephrine outflow
system with connections to mesolimbic and mesocor-
tical regions. The organic hypothesis of dPD may, there-
fore, be explained by dysfunction in the following brain
regions, neural networks, and neurotransmitters: (1)
subcortical nuclei and the frontal lobes; (2) cortical-
striatal-thalamo-cortical and basotemporal limbic neu-
ral networks; and (3) serotoninergic, noradrenergic and
dopaminergic neurotransmission mechanisms.
The natural history of dPD does not parallel the pro-
gression of physical symptoms, suggesting that it is an
independent process that might affect vulnerable
patients. There might be a triphasic relationship between
depression and stage of the illness, with higher frequen-
cies of depression occurring at the Hoehn and Yahr
stages I and III/IV23. A distinction between presumed
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“organic” and “psychological” etiologies does not contrib-
ute to our understanding, nor does it help us with diag-
nostic or therapeutic decisions, and should therefore
be abandoned. A more integrated neuropsychiatric
approach to body and mind should be encouraged.
Treatment of dPD—General Considerations
After confirming the diagnosis of dPD, the first step is
to initiate a plan to keep the patient safe by asking
about suicidal thoughts and about plans that the patient
may have for suicide. A long-term plan must then be
structured to minimize stress and increase quality of life.
Often a psychiatrist, social worker, and occupational
therapist can be helpful in this readjustment period. 
A description of the psychotherapeutic approaches is
beyond the scope of this article, but these approaches
can be effective alone or in combination with antidepre-
ssant drugs, particularly in relation to reactive depres-
sive episodes around the time of diagnosis. Although
there is insufficient evidence to support or refute the
value of exercise in reducing depression, exercise train-
ing has been shown to be beneficial with regards to
physical functioning, quality of life, strength, balance
and gait speed for PD24.
It is widely accepted that higher levels of de-
pression are found during the “off” periods in patients
with fluctuating PD; however, the response of de-
pression to long-term treatment with levodopa is
generally unsatisfactory. Levodopa is metabolized by
catechol-O-methyltransferase (COMT) using S-adenosyl-
L-methionine as the methyl donor, which leads to the
subsequent formation of homocysteine25. PD patients
with elevated homocysteine levels have a higher prev-
alence of cognitive impairment and depression26.
Studies have found that inhibition of COMT with tol-
capone, which has been shown to be helpful in the
treatment of major depressive disorder, or entacapone
in PD patients results in decreased plasma homocys-
teine levels27–29. However, tolcapone was banned from
the market owing to an increased risk of fulminant
hepatitis. To date, no controlled trials of entacapone
aimed at assessing antidepressant efficacy in PD have
been reported.
Amantadine, an antiparkinsonian agent with several
pharmacologic mechanisms, is known to ameliorate the
motor symptoms of PD. A literature review supported
the role of amantadine as an antidepressant30. A recently
published report showed that joint therapy with an
antidepressant and amantadine may be effective in
treatment-resistant unipolar depression31. It has been
shown that the D3 dopamine receptor agonist pram-
ipexole is effective in treating PD and non-PD depres-
sion32. In one prospective randomized trial, 1 mg or 5 mg
of pramipexole per day showed benefits comparable
to those of fluoxetine33. The evidence for ropinirole,
which is also selective for D3 but with less affinity than
that of pramipexole, as an antidepressant is limited.
In a retrospective review, ropinirole 0.25–1.5 mg daily
added to a tricyclic antidepressant (TCA) or selective
serotonin reuptake inhibitor (SSRI) was effective and
relatively well tolerated34. In conclusion, the replace-
ment of dopamine is ineffective or only partially effec-
tive in treating dPD patients.
There are several classes of antidepressant agents,
including TCA, SSRI, monoamine oxidase inhibitor, sero-
tonin noradrenergic reuptake inhibitor (SNaRI), nor-
adrenergic and specific serotoninergic antidepressant
(NaSSA), serotonin agonist and serotonin reuptake inhib-
itor (SARI), noradrenergic and dopaminergic reuptake
inhibitor (NaDRI), noradrenaline reuptake inhibitor,
amongst others. Until recently, there was insufficient
scientific data available to make an evidence-based
choice of antidepressants for treatment of dPD. In 2006,
the American Academy of Neurology practice parameter
on the treatment of depression, psychosis and demen-
tia in PD recommended that the TCA amitriptyline be
considered in the treatment of dPD; however, because of
its side effect profile, it may not necessarily be the first
choice of antidepressant35. A Cochrane review of trials
of antidepressants for people aged over 55 years con-
cluded that there is no significant difference in effi-
cacy across antidepressant classes, although TCAs have
been shown to be associated with a higher withdrawal
rate because of side effects36. Drug selection for the indi-
vidual patient should, therefore, depend on coexisting
medical conditions, concomitant drug therapy, expected
side effect profile of the given antidepressant, and cost
of the antidepressant.
Randomized controlled studies concerning the effi-
cacy of TCAs in PD showed that imipramine, nortriptyline
and desipramine were effective in treating depression
and may even reduce motor symptoms37. The anticho-
linergic and antihistamine effects of TCAs can be ben-
eficial in the treatment of drooling and tremor in PD,
and in sedation of agitated patients, respectively. How-
ever, the unwanted adverse reactions of anticholinergic
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effects may cause dry mouth, blurred vision, urinary
retention, cognitive symptoms, or cardiac conduction
abnormalities, especially in elderly patients. Although
no antidepressant is ideal, many clinicians begin with
one of the SSRIs because of their ease of use, safety 
in overdose, and generally high tolerability to them38.
A survey from the Parkinson’s Study Group found that
51% of these physicians use SSRIs first when imple-
menting drug therapy, in contrast with the 41% who
use TCAs and the 8% who use “other” drugs39. The most
commonly encountered adverse events with SSRIs are
nausea, headache, tremor, sweating, and sexual dys-
function. Theoretically, increased serotoninergic activ-
ity may inhibit dopamine release from dopaminergic
neurons, which may aggravate the motor symptoms 
of PD. However, studies in patients with PD have
shown that worsening of motor symptoms during SSRI
therapy is a rare phenomenon40,41. The SSRI citalopram
was observed to improve not only depression but also
bradykinesia in patients with PD treated with levo-
dopa42. Regarding the potential for drug interactions,
citalopram has a much lower potential for interactions
than other SSRIs.
In PD patients who are receiving selegiline (a
monoamine oxidase B inhibitor), there has been con-
cern that mixing SSRIs with selegiline might precipi-
tate serotonin syndrome. In a large survey, serotonin
syndrome was noted in only 0.24% of patients receiv-
ing an SSRI with selegiline43. Selegiline should not be
considered an absolute contraindication to the use of
SSRIs. Venlafaxine (a SNaRI) is a useful third-line anti-
depressant that can be tried if there has been an
unsatisfactory response to an adequate trial of two
other antidepressants. However, it has not been for-
mally tested in PD patients. Both venlafaxine and
SSRIs can cause hyponatremia, serotoninergic effects,
and discontinuation syndrome. Cardiotoxicity (tachy-
cardia, hypertension and prolongation of corrected QT
interval) is more problematic with venlafaxine than
with SSRIs, but it usually causes fewer anticholinergic
effects than TCAs.
Trazodone, an SARI that induces a sedating effect,
has been used to treat agitated depression without
causing significant anticholinergic side effects. Common
side effects of trazodone include orthostasis, dizziness,
and sedation. Bupropion (a NaDRI) has been reported
to induce a modest improvement in motor symptoms
in some PD patients44. On the other hand, there are
some reports of patients treated with bupropion who
developed acute dystonia or parkinsonism45. It tends
to be more “activating” than many other antidepres-
sants and may, therefore, ameliorate fatigue. Common
side effects include insomnia, agitation, constipation,
dry mouth, excessive sweating, tremor, and weight loss.
At high dosages, bupropion may causes psychosis and
seizures. Mirtazapine (a NaSSA) has an advantage over
other antidepressants in that it decreases anxiety, nau-
sea, and insomnia. This drug is also reported to have a
potential additional benefit in the treatment of tremor
and levodopa-induced dyskinesias46. However, a case
series reported four patients with PD who developed
sleep-related behavioral problems, including noctur-
nal confusion, talking during sleep and hallucinations,
while taking mirtazapine47. In conclusion, antidepres-
sant therapy should be selected on the basis of each
individual’s needs.
Treatment of dPD—Individual 
Patient Considerations
As PD progresses, the severity of depression may
change. Antidepressants that are useful early in PD
may be less useful later. In addition, medical comor-
bidity and associated symptoms, such as anxiety, pain,
psychosis and sleep disorders, affect the choice of an
antidepressant drug. These factors have not been sys-
tematically studied and the following should be con-
sidered accordingly.
Depressive Patients in Early Stage PD
It is well known that treatment with a dopamine ago-
nist in early stage PD can delay the onset of dyskinesia
and motor fluctuations. Preliminary studies have report-
ed the effectiveness of the dopamine agonist pram-
ipexole as an antidepressant in both non-PD and PD
populations35,48. It is important to determine whether
the combination of a dopamine agonist and an anti-
depressant is superior to either alone, and whether
dopamine agonists offer prophylaxis against the devel-
opment of dPD. Given the known antidepressant ac-
tivity of the dopamine agonist pramipexole, initiating
treatment with it is reasonable. However, it should be
noted that dopamine agonists are more likely to trig-
ger delusions and hallucinations than levodopa in older
patients with cognitive changes.
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Depressed PD Patients with Nocturnal 
Sleep Disturbances
Nocturnal sleep disturbances that commonly occur with
PD include insomnia, motor symptoms such as restless
legs or nocturnal off periods, urinary symptoms, as well
as neuropsychiatric symptoms such as vivid dreams, hal-
lucinations or rapid eye movement sleep behavior dis-
order (RBD)49. Depression is frequently associated with
nighttime wakefulness, including inability to fall asleep
or to remain asleep. In patients in whom sleep problems
begin following the initiation or increase in dosage of
antiparkinsonian medication, a reduction in dose or
discontinuation of the medication may be beneficial.
Selegiline is usually taken twice daily, and to minimize
the stimulatory effect attributed to its amphetamine
derivatives, the second daily dose should not be taken
after 16:00. For nocturnal off periods, certain treatment
strategies provide sustained antiparkinsonian effects.
For example, controlled-release formulations of levo-
dopa have been shown to improve nocturnal akinesia,
tremor and rigidity, and to increase sleep efficiency,
with a reduction in sleep fragmentation50.
Specific sleep-related pathologies, such as restless
legs, periodic limb movements, sleep apnea and RBD,
have to be treated according to the standard therapies
for these disorders. It is commonly believed that rest-
less legs can be exacerbated by antidepressant agents,
thus complicating the treatment of dPD patients. Rest-
less legs can be effectively treated with a dopamine
agonist. According to a recently published report, bupro-
pion was shown to be useful in the treatment of patients
with both depression and restless legs51. Diagnosis of RBD
currently requires the presence of established clinical
criteria; polysomnography is needed to confirm the diag-
nosis. TCAs are known to precipitate RBD. Levodopa
may be very effective in patients with PD and RBD.
Clonazepam, when taken nightly, is highly effective in
the treatment of RBD, with little evidence of tolerance
or abuse.
Patients with insomnia secondary to nighttime con-
fusion or “sundowning,” or hallucinations and psychosis,
may respond well to atypical neuroleptics, such as cloza-
pine and quetiapine; however, these patients should
be monitored for symptoms of adverse effects52. For
insomnia, it is important to have patients practice good
sleep hygiene. TCAs can be useful, not only to treat
depression and maintain sleep, but also to reduce uri-
nary frequency in some patients. The most sedating to
the least sedating in this class of medicines are as fol-
lows: doxepin, followed by imipramine, desipramine,
and nortriptyline19. Among SSRIs, paroxetine is the most
sedative drug and, therefore, is possibly beneficial for
insomnia37. Trazodone and mirtazapine are also sedat-
ing antidepressants and may be used alone. Doses
should be started low and titrated slowly to provide a
restful night’s sleep without causing sedation the next
morning. Zolpidem is a good alternative and, unlike traz-
odone, is not associated with orthostatic hypotension,
although it has not been approved for long-term use.
Depressed PD Patients with Bladder
Dysfunction
Bladder dysfunction in PD may take an upper or lower
motor neuron form and may involve the sphincter or
detrusor, or both. Classically, the upper motor neuron
defect will produce an overactive bladder with symp-
toms of urinary urgency and frequency, while a lower
motor neuron defect will produce retention with over-
flow incontinence if it involves the detrusor, or leakage
if it involves the sphincter. The prevalence of urinary
disturbances ranges from 27% to 39%53. The most com-
mon complaint is nocturia, followed by frequency and
urgency, and symptoms correlate with rigidity severity
and with years of evolution of PD54. The urinary ques-
tionnaire allows us to identify the type of bladder dys-
function and to select patients who will benefit the
most from medications. An overactive bladder will often
respond to anticholinergics, such as oxybutynin and
tolterodine. Oxybutynin effectively controls detrusor
hyperactivity; however, its anticholinergic side effects
limit its use in the elderly and in those with dementia55.
Tolterodine has a more favorable side effect profile
than oxybutynin, and it is available in a long-acting for-
mulation56. Antidepressants with antimuscarinic effects,
such as imipramine, nortriptyline and doxepin, may
treat nocturia, but should be used with caution because
of their side effect profiles. In contrast, an underactive
bladder with mild retention and a weak stream may
benefit from a muscarinic cholinergic agonist, such as
bethanechol. Sphincteric dysfunction with symptoms
of urinary incontinence or leakage may be treated with
alpha-adrenergic blockers to improve bladder empty-
ing, but the side effect of hypotension often limits its
usage57. PD patients should be referred for urody-
namic evaluation if the response to anticholinergics is
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unsatisfactory, if incontinence is a problem, or when
an in-dwelling catheter is needed58.
Depressed PD Patients with Heart and
Vascular Diseases
TCAs are associated with documented adverse cardio-
vascular effects, including increases in heart rate, ortho-
static hypotension and conduction delays. Use of TCAs
in patients with heart disease carries a proven increased
risk of cardiac morbidity and mortality59. Among TCAs,
nortriptyline is less likely to cause orthostatic hypoten-
sion than amitriptyline or imipramine. The SSRIs appear
to be relatively safe and effective treatment options for
depression in patients with concomitant ischemic heart
disease. According to investigators, SSRIs and SNaRIs
are first-line antidepressants for moderate to severe
depression, especially in patients with coexisting car-
diovascular disease, with bupropion and mirtazapine
as second-line agents60. A large-scale randomized trial
suggested that sertraline therapy may very likely im-
prove cardiac outcome61. Venlafaxine should not be used
in patients with uncontrolled hypertension, and regu-
lar blood-pressure monitoring is recommended for all
patients taking this drug. However, this hypertensive
effect may be desirable in PD patients with postural
hypotension. Trazodone should be used with caution
in PD patients prone to orthostatic hypotension and
ventricular arrhythmias19.
Depressed PD Patients with Pain Comorbidity
Depression and painful symptoms commonly occur
together. The frequency of pain in patients with PD
ranges from 30% to 70% according to the literature,
and is mainly pain of muscular origin, followed by oste-
oarticular and neurogenic painful syndromes62,63. Some
disorders, such as foot dystonia, restless legs, akathisia
and musculoskeletal pain, may represent inadequate
levels of dopaminergic stimulation64. The aim of drug
treatment is to reduce the frequency and duration of
“off” states. Positron emission tomography has revealed
that the pain threshold is lower in these patients but
returns to normal after levodopa administration65. When
pain occurs with excessive dopaminergic stimulation,
it is usually associated with neck/facial dystonia or pain-
ful dyskinesia. Reducing the dosage or discontinuing
adjunctive drugs, such as selegiline, dopamine agonists
and COMT inhibitors, usually is the first step. Levodopa
dose reduction may be necessary, but will almost cer-
tainly result in increased “off” time. Nonspecific pains
not specifically related to dopaminergic medications
can be difficult to treat. TCAs are thought to affect pain
transmission in the spinal cord by inhibiting the reup-
take of norepinephrine and serotonin, both of which
influence descending pain pathways. Amitriptyline
and its metabolite nortriptyline have the best docu-
mented efficacy in the treatment of neuropathic and
non-neuropathic pain syndromes. Bupropion and ven-
lafaxine also have proven to be effective in patients
with neuropathic pain66. Tramadol, a centrally acting
analgesic, is structurally similar to venlafaxine, sharing
both serotoninergic and noradrenergic properties. Just
as venlafaxine may be helpful with chronic pain in some
individuals, tramadol may possibly exert an antidepres-
sant effect in certain patients, particularly those with
chronic pain67.
Depressed PD Patients with Anxiety
Anxiety often accompanies depression, and up to 40%
of patients with PD may have significant anxiety68. SSRIs,
such as citalopram, escitalopram and paroxetine, may
be effective in treating anxiety and depression in patients
with PD. New-generation antidepressants, such as venla-
faxine and mirtazapine, may be an alternative choice
for patients who are depressed and anxious69. Short-
term use of benzodiazepines, such as lorazepam, clonaz-
epam or alprazolam, may be beneficial in non-suicidal
depressed patients with severe anxiety70. Benzodiaze-
pines can be problematic in elderly patients with regard
to impairment of arousal, cognition and balance. Beta
blockers have been used to lessen tremor in PD and
may have a small anti-anxiety effect71.
Depressed PD Patients with Psychosis
Psychosis in the form of hallucination or illusion and
typically visual, usually occurs in patients with advanced
disease who are receiving PD pharmacotherapy. The
first step in treatment is to exclude potential medical
and environmental causes. Antiparkinsonian medica-
tions must be reduced or limited to those that are nec-
essary to preserve motor function. Based on expert
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opinion, reduction or discontinuation of medications
should be carried out in the following order: anticholin-
ergics, selegiline, amantadine, dopamine agonists, COMT
inhibitors, controlled-release levodopa, and immediate-
release levodopa72. Non-PD medications, such as anti-
muscarinic agents used for bladder hyperactivity, or
anxiolytics can be discontinued as well. Tapering and
discontinuing one drug at a time, rather than tapering
all of the drugs simultaneously, is recommended. Cholin-
esterase inhibitors (e.g., rivastigmine) have been shown
in open-label studies to reduce psychosis in PD and to
improve cognition73. In addition to antidepressants, an
atypical antipsychotic is usually required. A large num-
ber of PD patients have been successfully treated with
clozapine74. Because quetiapine does not require any
blood monitoring and clozapine does, quetiapine has
become the initial antipsychotic of choice for most PD
experts. Quetiapine appears to be safe in terms of
motor functioning, but evidence about its efficacy is
not compelling75. Other atypical antipsychotics, such as
olanzapine and risperidone, have been found to worsen
motor function in PD patients76.
Body Weight Changes Associated with
Antidepressant Use
Patients with PD appear to be at greater nutritional
risk. In fact, PD patients were four times more likely to
report weight loss greater than 4.5 kg than matched
control subjects77. Various factors contribute to weight
loss in PD. Reduced energy intake and/or increased
energy expenditure have been postulated as the cause78.
The disease itself eventually reduces a person’s ability
to chew and swallow. Rigidity, tremor, and levodopa-
induced dyskinesia may increase energy expenditure.
Depression and cognitive changes can further interfere
with normal nutrition. The long-term effect of dopa-
minergic treatment on body weight is not well known.
One study reported that previously untreated PD patients
experienced a significant loss of weight 2 years after
starting levodopa79. In contrast, pramipexole produced
a significant weight increase, as well as motor and
mood improvement80. Adequate nutrition and weight
stabilization are important for dPD patients. The body
weight of dPD patients should be monitored monthly,
and a patient’s nutrition should be supplemented with
sufficient amounts of vitamin D and calcium to reduce
the risk of hip fractures and to strengthen bone density81.
The choice of antidepressant in dPD is based on the
condition of the patient and the properties of the anti-
depressant. Marked weight gain frequently occurs dur-
ing treatment with most TCAs, while SSRIs may induce
weight loss during the first few weeks, although some
of them have been shown to induce weight gain dur-
ing long-term treatment82. Among TCAs, nortriptyline
has a neutral effect on weight change83. Among SSRIs,
paroxetine seems to be most prone to cause weight gain,
whereas citalopram may not produce significant changes
in body mass84. New-generation antidepressants have
been associated with various patterns of change. Venla-
faxine does not appear to cause weight changes. Mirtaza-
pine may be placed between the SSRIs and the TCAs in
terms of relative risk of weight gain, and bupropion
may be the only modern agent to lower weight85.
Depressed PD Patients Resistant or 
Refractory to Antidepressants
The most common cause of failure in treating depres-
sion is not the 2–3 weeks it takes for the drugs to have
an effect, or the use of too low a dose69. The most
common cause of failure is related to side effects.
Patients with comorbid anxiety disorders may be espe-
cially prone to side effects of medications, leading to
noncompliance.
Medications should be used at sufficient doses and
over sufficient time to treat depression successfully
and to prevent recurrences. As a general guideline, if
patients are partial responders at 6 weeks, they will
likely be full responders by 12 weeks. Thus, changing
medication is not indicated in this context. However, if
patients are only partial responders at 12 weeks, switch-
ing to a new agent is advised86. Two broad treatment
options exist for switching antidepressants for depressed
patients who fail to respond to a SSRI: either a second
course of SSRI therapy or a different class of antide-
pressants. Recently, a meta-analysis of four clinical trials
showed that patients who switched to a non-SSRI anti-
depressant (bupropion, mirtazapine, venlafaxine) were
more likely to experience remission than patients who
switched to a second SSRI87.
For PD patients who are suicidal, have severe treat-
ment resistance or are unable to wait for a response to
antidepressants, electroconvulsive therapy (ECT) should
be considered88. ECT can be effective in alleviating 
depressive symptoms and has been shown to have at
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least short-term benefits in alleviating motor symp-
toms in PD patients. These gains are not without com-
plications, which should be carefully weighed against
the benefits89. Repetitive transcranial magnetic stimu-
lation (rTMS) uses an electric coil to generate magnetic
fields that stimulate the cerebral cortex. It is very well
tolerated by patients and, in contrast to ECT, does not
require the use of anesthesia and does not appear to
cause seizures or cognitive deficits. Given the results of
published studies, high-frequency rTMS applied to the
left dorsolateral prefrontal cortex or low-frequency
rTMS applied to the right hemisphere seems to be
effective in alleviating mood symptoms in PD, and
may result in cognitive and motor function improve-
ment90. The drawbacks of rTMS include a short-lived
therapeutic effect, a muscle tension-type headache at
the site of stimulation, and a risk of seizures. At pres-
ent, the use of rTMS in major depression and in dPD is
still considered investigational, and there is still no
standard protocol for the selection of the region, or
intensity and frequency of stimulation. Additional com-
parative studies are warranted.
Conclusion
Depression appears to be a common but under-
recognized and undertreated symptom of PD. Early
recognition of depression is essential for the care of
patients with PD, and the importance of a multi-
disciplinary approach cannot be overemphasized.
Further research is needed to improve the diagnostic
accuracy for dPD in order to more closely match clini-
cal presentations. Standardized rating scales with
proven validity in dPD can be useful to identify and to
follow the severity of depression. Presently, there are
no established first-choice antidepressant drugs for
dPD, and, therefore, the selection of an antidepressant
will be largely driven by the differences in the side
effect profiles of the available drugs and coexisting
medical conditions of the patient. Available clinical
evidence is primarily from open trials, which show
that TCAs and SSRIs are both effective treatments.
There is limited evidence that dopamine agonists may
be effective as augmenting agents. It is clear that
larger randomized controlled trials are needed to fur-
ther evaluate the efficacy of antidepressant treatments
and to allow for the development of evidence-based
treatment guidelines.
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